Which new partners were added in Q2, and what is the expected revenue contribution from these new partnerships? | OABI (Aug 06, 2025) | Candlesense
OABI

Which new partners were added in Q2, and what is the expected revenue contribution from these new partnerships?

Answer

The excerpt you provided from OmniAb’s Q2 2025 earnings release does not list the specific names of the new partners added during the quarter, nor does it disclose the projected revenue contribution that those new partnerships are expected to generate.

  • New partners: The press‑release headline says that OmniAb “reached 100 active partners,” indicating that the company added a number of new partners in Q2, but the summary you have does not identify them individually (e.g., no company names or sectors are mentioned).

  • Expected revenue contribution: Likewise, the summary contains no figures or guidance about the incremental revenue that these new partners are anticipated to bring to OmniAb’s top line.

What you can do next

If you need the exact partner names and the revenue outlook associated with them, you will have to consult the full earnings release (or the accompanying investor presentation) that OmniAb filed with the SEC or posted on its corporate website. Those documents typically include:

  1. A table or narrative listing the newly‑added partner organizations (often broken out by therapeutic area, geography, or partnership type).
  2. Management’s financial guidance or commentary on the incremental revenue expected from those partners (e.g., “the new partners are projected to contribute $X million in revenue for FY 2025”).

You can locate that information by:

  • Visiting OmniAb’s Investor Relations page and downloading the Q2 2025 earnings release (often provided as a PDF or HTML release).
  • Checking the Form 8‑K filing with the SEC for the same quarter, which must include the full press release.
  • Looking for any earnings call transcript (often posted on platforms like Seeking Alpha, Motley Fool, or directly on the company site) where executives may discuss partner additions and revenue expectations in more detail.

Until you access the complete filing, the specific partner names and their expected revenue contribution remain unavailable from the brief summary you have shared.

Other Questions About This News

Are there any changes in the company's debt, share repurchase, or dividend policies following these results? What is the company's current cash position, burn rate, and runway after the reported results? What were the revenue, earnings, and cash flow figures for Q2 2025 and how did they compare to analyst expectations? What potential catalysts or risks could affect the stock price in the short term (e.g., upcoming data releases, regulatory milestones)? What are the long‑term implications for growth and profitability if the company continues to add partners at this rate? How does the valuation (PE, EV/EBITDA, etc.) of OmniAb compare to peer companies after this announcement? What is the average revenue per partner and how does it trend over time? How does the achievement of 100 active partners compare to prior quarters and to competitors in the biotech/partner platform space? Did the company provide guidance for Q3 2025 and the full fiscal year, and what are the key assumptions behind that guidance?